Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead’s Robust Expanded Access For Remdesivir Signals Confidence In Study Enrollment

Executive Summary

US FDA has granted about 250 COVID-19 patients expanded access to Gilead’s investigational antiviral; the adaptive trial now underway in US aims for 400 patients.

You may also be interested in...



Expanded Access Guidance On COVID-19 Will Inform US FDA’s Post-Pandemic Policies

In line with Commissioner Hahn’s view that lessons learned during the pandemic will have a lasting impact on FDA policies and procedures, new guidance on IRB review for individual patient access requests will be revised after the public health emergency ends to reflect agency’s implementation experience.

Gilead's Expanded Access Shift Offers New Data Collection Opportunities For Remdesivir

Pivot from individual- to multi-patient protocols for expanded access may help generate data to inform regulatory filings and even payer determinations for Gilead’s potential COVID-19 treatment.

Canada Supplements COVID-19 Testing By Invoking Emergency Provisions

The Canadian government has issued an interim order authorizing the import and sale of two new diagnostic test kits for COVID-19. Other companies making tests for the virus can apply for authorization under the order.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS141886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel